谷氨胺补充剂作为一种新的代谢治疗策略,用于LIG3依赖的慢性肠道伪阻塞
Chiara Diquigiovanni1, Nicola Rizzardi2, Erica Cataldi-Stagetti1
1Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Gastroenterology
|August 22, 2024
概括
基因链酶3 (LIG3) 突变导致线粒体功能障碍. 补充L-Glutamine改善了细胞能量生产和罕见遗传综合征患者的症状.
科学领域:
- 遗传学和分子生物学
- 细胞和线粒体生物学
- 胃肠病学和神经病学
背景情况:
- 鉴定了一种由DNA结合酶3 (LIG3) 突变引起的衰退性综合征.
- LIG3突变损害了线粒体DNA的维护和能量生产.
- 综合症呈现为慢性肠道伪阻塞,白脑病和神经性膀.
研究的目的:
- 在LIG3缺乏症中确定改变的分子通路.
- 开发有针对性的治疗方法,以解决细胞能量损害的问题.
- 评估l-Glutamine补充剂的治疗潜力.
主要方法:
- 在患者衍生纤维细胞上进行了全转录组分析.
- 评估了线粒体功能,线粒体和平衡.
- 使用l-氨酸补充剂并使用验证的问卷评估患者的症状.
主要成果:
- 突变纤维细胞显示了基因表达的放松调节,肌衰减和改变的平衡.
- 补充L-Glutamine可以改善纤维细胞生长率和ATP的产生.
- 在患者中,亲肠道l-谷氨治疗显著改善了胃肠道和胃肠外症状.
结论:
- LIG3 缺乏与线粒体功能障碍和细胞能量损害有关.
- 补充L-Glutamine证明了LIG3突变细胞和患者的治疗益处.
- 结果支持临床试验,研究LIG3相关疾病中的l-氨酸.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
329
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
329
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
228
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
228
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Drugs Affecting GI Tract Motility: Other Laxatives
178
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
178
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
92
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
92


